{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"This is the percentage of patients alive and progression-free at 6 months from initiation of treatment.","groups":[{"description":"cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks","id":"OG000","title":"Cisplatin, Pemetrexed, Bevacizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"patients progression free at 6 months","title":"Progression Free Survival Rate at 6 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}